Acta Medica (Hradec Kralove). 2025;68(2):45-49. doi: 10.14712/18059694.2025.18.
ABSTRACT
OBJECTIVE: To evaluate whether baseline serum creatinine is associated with survival outcomes in patients with advanced high-grade serous ovarian carcinoma undergoing neoadjuvant chemotherapy.
METHODS: We retrospectively analyzed 77 patients treated between 2009 and 2018. Patients were stratified by baseline serum creatinine levels (<84 vs. ≥84 µmol/L), and survival outcomes were assessed using Kaplan-Meier analysis.
RESULTS: No statistically significant differences in progression-free or overall survival were observed between groups. A trend toward shorter OS in the elevated creatinine group did not reach significance.
CONCLUSION: Baseline serum creatinine was not found to be a statistically significant prognostic marker in this cohort. These results highlight the need for adjusted analyses incorporating established prognostic factors in future research.
PMID:41064889 | DOI:10.14712/18059694.2025.18
